Home
Our Company
ProductsPress ReleasesPartneringCareersContact
Featured Post

Temporary Shortage of Quillivant® ER 20mg Chewable Tablets

May 19, 2025
Read More

January 5, 2021

KYE Pharmaceuticals Announces Approval of CORZYNA™ in Canada (ranolazine extended-release tablets)

Read More

October 28, 2020

KYE Pharmaceuticals Announces Commercial Availability of FIRDAPSE® in Canada

Read More

August 26, 2020

KYE Pharmaceuticals and Catalyst Pharmaceuticals Challenge Health Canada’s Decision to Overlook Firdapse® Data Exclusivity

Read More

August 18, 2020

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce Agreement to Make Firdapse® (amifampridine phosphate) Available to LEMS Patients in Canada

Read More

July 9, 2020

Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada

Read More
Follow us on LinkedIn!
Kye Pharmaceuticals © 2023. All Rights Reserved.  |  Web Design by Aquí.
ContactPrivacy PolicyTerms of Use
Kye Pharmaceuticals © 2023. All Rights Reserved.  Web Design by Aquí.